AI Agent & Copilot Podcast: Nandita Puri on How AI Is Revolutionizing Drug Discovery at Georgia Tech

In this episode of the AI Agent & Copilot Podcast, Giuseppe Ianni, podcast host and industry interviewer, is joined for a second time by Nandita Puri, PhD Researcher at Georgia Tech working at the intersection of bioinformatics and biochemistry. The conversation explores how AI is transforming drug discovery, accelerating hypothesis generation, reducing experimental costs, improving success rates, enabling rare disease research, and paving the way for virtual cell simulation. Key Takeaways AI Is Creating a New Drug Discovery Workflow: Puri describes a major transition from traditional laboratory-first research toward a hybrid approach combining computational and experimental science. Researchers can now use AI, machine learning, and pattern recognition to analyze massive biological datasets before conducting expensive laboratory work. According to Puri, "I see a healthy combination of 50% dry lab and wet-lab validation becoming the emerging standard." This shift allows scientists to move beyond manual analysis and leverage computational intelligence to generate stronger hypotheses, identify promising targets faster, and focus laboratory resources on the most promising opportunities. Higher Success Rates Mean Lower Costs and Less Waste: One of the most immediate benefits of AI in drug discovery is improved experimental efficiency. Puri notes that individual experiments can cost "$10,000-$12,000" and historically have carried significant failure risk. By consolidating fragmented datasets and identifying meaningful biological signals, AI helps researchers prioritize stronger hypotheses before entering the laboratory. Puri explained that some AI-assisted binder-development efforts achieved "40% 50% of success rate," compared with previous rates of "10% 5%." These improvements reduce wasted resources, shorten research timelines, and allow scientific teams to evaluate more potential treatments with the same budget. AI Is Unlocking Opportunities for Rare Disease Research: Rare diseases have historically faced funding and development challenges due to limited patient populations and expensive clinical validation requirements. Puri explains that AI is helping overcome these barriers by generating synthetic datasets, identifying hidden biological relationships, and revealing common signaling pathways between diseases. She notes that "AI is really, really helping rare disease industry to go forward." Visit Cloud Wars for more.